ISIN | LU2226244361 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Galileo – Biotech Innovation Fund BC USD |
Fund Provider |
IPConcept (Luxemburg) S.A.
Zürich, Switzerland Phone: +352 260248-1 E-Mail: info.lu@ipconcept.com Web: www.ipconcept.com |
Fund Provider | IPConcept (Luxemburg) S.A. |
Representative in Switzerland |
IPConcept (Schweiz) AG Zürich Phone: +41 044 224 32 09 |
Distributor(s) | Bellecapital AG |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark. |
Peculiarities |
Current Price * | 35.55 USD | 08.05.2025 |
---|---|---|
Previous Price * | 36.15 USD | 07.05.2025 |
52 Week High * | 65.08 USD | 17.07.2024 |
52 Week Low * | 33.21 USD | 09.04.2025 |
NAV * | 35.55 USD | 08.05.2025 |
Issue Price * | 35.55 USD | 08.05.2025 |
Redemption Price * | 35.55 USD | 08.05.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 26,830,755 | |
Unit/Share Assets *** | 25,887,424 | |
Trading Information SIX |
YTD Performance | -24.31% |
30.12.2024 - 08.05.2025
30.12.2024 08.05.2025 |
---|---|---|
YTD Performance (in CHF) | -31.11% |
30.12.2024 - 08.05.2025
30.12.2024 08.05.2025 |
1 month | +3.25% |
08.04.2025 - 08.05.2025
08.04.2025 08.05.2025 |
3 months | -21.11% |
10.02.2025 - 08.05.2025
10.02.2025 08.05.2025 |
6 months | -37.90% |
08.11.2024 - 08.05.2025
08.11.2024 08.05.2025 |
1 year | -42.91% |
08.05.2024 - 08.05.2025
08.05.2024 08.05.2025 |
2 years | -43.46% |
08.05.2023 - 08.05.2025
08.05.2023 08.05.2025 |
3 years | -43.25% |
10.05.2022 - 08.05.2025
10.05.2022 08.05.2025 |
5 years | -76.30% |
31.03.2021 - 08.05.2025
31.03.2021 08.05.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Arcellx Inc | 9.99% | |
---|---|---|
Krystal Biotech Inc | 9.23% | |
Alnylam Pharmaceuticals Inc | 4.57% | |
Q32 Bio Inc | 4.19% | |
Stoke Therapeutics Inc | 3.51% | |
Iovance Biotherapeutics Inc | 3.45% | |
Sarepta Therapeutics Inc | 2.94% | |
Silence Therapeutics PLC ADR | 2.75% | |
Rocket Pharmaceuticals Inc | 2.75% | |
Voyager Therapeutics Inc | 2.42% | |
Last data update | 31.10.2024 |
TER | |
---|---|
TER date | |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | |
Ongoing Charges *** | 0.44% |
SRRI ***
|
|
SRRI date *** | 30.04.2025 |